Indian multinational pharmaceutical company headquartered in Mumbai, manufacturing and selling pharmaceutical formulations and active pharmaceutical ingredients in more than 100 countries; the largest pharmaceutical company in India and fourth largest specialty generic pharmaceutical company globally.
相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1983
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- Multiple high-profile ANDA litigation settlements were resolved in the second and third quarters of 2025, involving major pharmaceutical companies and generic manufacturers across diverse therapeutic areas. - Settlement agreements typically resulted in patent validity acknowledgments and injunctions against generic manufacturers, with most claims dismissed without prejudice while allowing FDA approval processes to continue. - Notable settlements included complex multi-patent disputes for blockbuster drugs like Rinvoq, Jardiance, Xifaxan, and Biktarvy, demonstrating the ongoing importance of patent protection strategies in pharmaceutical innovation.
- Sun Pharmaceutical's manufacturing facility in Halol, India failed another FDA inspection last month due to serious quality control issues and contamination concerns. - The FDA issued a 19-page report detailing problems with sterility, environmental conditions, and cleanliness practices at the world's largest generic drugmaker's key facility. - This latest inspection failure continues a pattern of regulatory violations at the plant dating back nearly a decade, raising ongoing concerns about the company's ability to ensure proper manufacturing standards. - The inspection findings highlight persistent difficulties in following proper procedures and preventing medicine contamination at this critical Sun Pharma production site.
- The global photodynamic therapy market is projected to surpass $6 billion by 2030, driven by technological advances in LED-based light delivery systems and improved photosensitizer formulations. - Recent clinical developments include Sun Pharmaceutical's FDA-cleared BLU-U Blue Light PDT Illuminator and Biofrontera's successful Phase 3 study of Ameluz® for superficial basal cell carcinoma treatment. - Comprehensive meta-analysis evidence demonstrates PDT's effectiveness varies by cancer type, with strong benefits for cholangiocarcinoma when combined with stenting and superior cosmetic outcomes for skin cancers compared to traditional treatments.
- Eisai and Merck successfully defended a key patent for cancer drug Lenvima against Shilpa Medicare's challenge, with a federal judge ruling the patent describes the invention clearly and in sufficient detail. - The patent victory covers purified lenvatinib mesylate and blocks Shilpa's generic version from FDA approval until the patent expires in February 2036. - Lenvima generated over $1 billion in alliance revenues for MSD last year and $1.51 billion in US sales for Eisai, making it a significant blockbuster cancer treatment. - The drug is widely used alongside Keytruda as first-line therapy for kidney cancer and second-line treatment for endometrial cancer, having treated over half a million patients worldwide.
